Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC. Wu H, et al. Among authors: ikeda s. Int J Nanomedicine. 2015 Feb 10;10:1201-9. doi: 10.2147/IJN.S62911. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25709442 Free PMC article.
Establishment of a HFpEF model using female Dahl salt-sensitive rats: a valuable tool for elucidating the pathophysiology of HFpEF in women.
Nakashima H, Shinohara K, Matsumoto S, Nakashima R, Yoshida D, Ono Y, Miyamoto R, Ikeda S, Matsushima S, Hashimoto T, Katsuki S, Ikeda M, Yoshida K, Kinugawa S, Abe K. Nakashima H, et al. Among authors: ikeda s. Hypertens Res. 2024 Nov 28. doi: 10.1038/s41440-024-02025-7. Online ahead of print. Hypertens Res. 2024. PMID: 39609645
Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
Hirano H, Kataoka K, Yamaguchi T, Wagner AD, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Mizusawa J, Sano Y, Shiomi A, Shiozawa M, Ohue M, Adachi T, Ueno H, Ikeda S, Komori K, Tsukamoto S, Takashima A, Kanemitsu Y. Hirano H, et al. Among authors: ikeda s. Eur J Cancer. 2024 Nov 19;214:115139. doi: 10.1016/j.ejca.2024.115139. Online ahead of print. Eur J Cancer. 2024. PMID: 39579641
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Chatani R, Shibata T, Nishimoto Y, Ogihara Y, Doi K, Oi M, Shiga T, Sueta D, Kim K, Tanabe Y, Koitabashi N, Takada T, Ikeda S, Nakagawa H, Tsukahara K, Shoji M, Sakamoto J, Hisatake S, Ogino Y, Fujita M, Nakanishi N, Dohke T, Hiramori S, Nawada R, Kaneda K, Ono K, Kimura T; ONCO PE Trial Investigators. Yamashita Y, et al. Among authors: ikeda s. Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758. Online ahead of print. Circulation. 2024. PMID: 39556015 Free article.
4,535 results